SCHERING-PLOUGH NITRO-DUR NITRO PATCH SUPPLEMENTAL NDAs APPROVED by FDA on April 4, making the nitroglycerin transdermal infusion system the first pre-1962 nitroglycerin product in a patch form to have fully approved NDAs. FDA asked manufacturers of nitro patches to submit NDAs for the DESI drugs in a Federal Register notice of July 15, 1993 ("The Pink Sheet" July 19, 1993, T&G-2). Nitro-Dur and Ciba/Summit's Transderm-Nitro were then deemed the "reference drugs."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
